Agency Forms Undergoing Paperwork Reduction Act Review, 14401-14402 [2011-6106]
Download as PDF
<![CDATA[
14401
Federal Register / Vol. 76, No. 51 / Wednesday, March 16, 2011 / Notices
about one quarter of people who have a
PE.
The Division of Blood Disorders
submitted questions to the 2007
HealthStyles survey to determine the
public’s knowledge of DVT, its common
symptoms, and risk factors. Although
over 60% of respondents identified pain
and swelling as symptoms, 60% did not
identify tenderness (often the first sign
of DVT) as a symptom. Only 38% of
respondents knew that a DVT was a
blood clot in a vein, and most could not
identify common risk factors for DVT
such as sitting for a long period of time
(e.g., during air travel); having a leg or
foot injury; having a family member
who has had a DVT; taking birth control
pills; or getting older; and certain
groups could not identify risk factors
that specifically applied to their risk.
The results of this survey demonstrates
the need for greater awareness of DVT,
and its risk factors and the data show
that there are many opportunities to
develop audience specific messages that
are age specific and culturally
appropriate.
Much of the morbidity and mortality
associated with DVT/PE could be
prevented with early and accurate
diagnosis and management. DVT/PE is
preventable. It is important for people to
developed from insights emerging from
this exploratory research phase. The
Contractor will conduct eight (8) focus
groups with nine (9) participants in
each focus group during the second
stage to test the message concepts and
identify possible ways to present the
messages. It is estimated that 144
respondents will have to be screened in
order to recruit 72 focus group
participants. The informed consent will
take approximately 6 minutes to
complete, for a total burden of 7 hours.
The Contractor selected will work
with CDC to identify and recruit focus
group participants. Formative research
participants will include adults (aged
25–64) who have been hospitalized in
the last year and seniors (aged 65–80).
Message testing participants will
include adults (aged 25–64) who have
been hospitalized in the last year and
seniors (aged 65–80). Participants will
be recruited to participate in one of
sixteen in-person focus groups that will
be conducted in the following cities:
• Atlanta, Baltimore, Pittsburgh, and
Tampa (formative research task), and
• Atlanta, Baltimore, Pittsburgh, and
Tampa (message testing task)
There are no costs to the respondents
other than their time.
be able to recognize the signs and
symptoms and know when to seek care
and available treatment. Individuals,
families, and their support communities
can reduce their risk by understanding
DVT/PE and its risk factors. DVT/PE
affects people of all races and ages.
Many of the acquired risks such as
obesity, advanced age, air travel,
chronic diseases, cancer, and
hospitalization are increasing in the
United States, and we can expect to see
increasing numbers of people affected
by DVT/PE.
The CDC’s Division of Blood
Disorders will conduct focus groups to
develop messaging concepts that will be
used in a public awareness campaign to
build knowledge and awareness of DVT/
PE, increase recognition of the
symptoms and risk factors for DVT/PE,
and empower people to take action.
The project will address these
objectives in two stages: In the first stage
the Contractor selected will conduct
eight (8) formative focus groups with
nine (9) participants in each focus group
to explore consumer knowledge,
attitudes, and beliefs (KABs) toward
DVT. It is estimated that 144
respondents will have to be screened in
order to recruit 72 focus group
participants. Message concepts will be
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Average
burden per
response (in
hours)
Number
responses per
respondent
Total burden
hours
Type of respondent
Form name
Seniors (65–80) ................................
Adults (25–64) recently hospitalized
Formative research stage: Participant Screener and Recruitment
Script.
Message testing stage: Re-screener
144
1
5/60
12
144
1
9/60
22
Formative Research stage: Moderator’s Guide.
Formative Research stage: Informed
Consent.
Message testing stage: Moderator’s
Guide.
Message testing stage: Informed
Consent.
...........................................................
72
1
1.5
108
72
1
6/60
7
72
1
1.5
108
72
1
6/60
7
........................
........................
........................
264
Seniors (65–80) ................................
Adults (25–64) recently hospitalized
Seniors (65–80) ................................
Adults (25–64) recently hospitalized
Seniors (65–80) ................................
Adults (25–64) recently hospitalized
Seniors (65–80) ................................
Adults (25–64) recently hospitalized
Seniors (65–80) ................................
Adults (25–64) recently hospitalized
Total ...........................................
Dated: March 10, 2011.
Carol E. Walker,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
jlentini on DSKJ8SOYB1PROD with NOTICES
[FR Doc. 2011–6107 Filed 3–15–11; 8:45 am]
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
[30-Day–11–0338]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
VerDate Mar<15>2010
16:56 Mar 15, 2011
Jkt 223001
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
E:\FR\FM\16MRN1.SGM
16MRN1
14402
Federal Register / Vol. 76, No. 51 / Wednesday, March 16, 2011 / Notices
Proposed Project
Annual Submission of the Ingredients
Added to, and the Quantity of Nicotine
Contained in, Smokeless Tobacco
Manufactured, Imported, or Packaged in
the U.S. (OMB No. 0920–0338, exp. 4/
30/2011)—Extension—Office on
Smoking and Health, National Center
for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC), Office on Smoking
and Health (OSH) has the primary
responsibility for the Department of
Health and Human Services (HHS)
smoking and health program. HHS’s
overall goal is to reduce death and
disability resulting from the use of
smokeless tobacco products and other
forms of tobacco use through programs
of information, education and research.
Since 1994, as required by the
Comprehensive Smokeless Tobacco
Education Act of 1986 (CSTHEA, 15
U.S.C. 4401 et seq., Public Law 99–252),
CDC has collected information about the
ingredients used in smokeless tobacco
products and their nicotine content.
Respondents are commercial smokeless
tobacco product manufacturers,
packagers, or importers (or their
representatives), who are required by
the CSTHEA to submit ingredient
reports to HHS on an annual basis.
Respondents are not required to
submit specific forms; however, they are
required to meet reporting guidelines
and to submit the ingredient report by
chemical name and Chemical Abstract
Service (CAS) Registration Number,
consistent with accepted reporting
practices for other companies currently
required to report ingredients added to
other consumer products. Typically,
respondents submit a summary report to
CDC with the ingredient information for
multiple products, or a statement that
there are no changes to their previously
submitted ingredient report.
Ingredient reports for new products
are due at the time of first importation.
Thereafter, ingredient reports are due
annually on March 31. Information is
submitted to OSH by mailing a written
report on the respondent’s letterhead, by
CD, three-inch floppy disk, or thumb
drive. Electronic mail submissions are
not accepted.
Upon receipt and verification of the
annual ingredient and nicotine data
reports, OSH issues a Certificate of
Compliance to the respondent. OSH also
uses the information to report to the
Congress (as deemed appropriate)
discussing the health effects of these
ingredients.
In this Extension request, there are no
changes to the estimated number of
respondents, the estimated burden per
response, or the information collection
methods. There are no costs to
respondents other than their time. The
total estimated annualized burden hours
are 18,843.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Smokeless Tobacco Manufacturers, Packagers, and Importers ................................................
11
1
1,713
Dated: March 10, 2011.
Carol E. Walker,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2011–6106 Filed 3–15–11; 8:45 am]
BILLING CODE 4163–18–P
HHS/CDC is publishing this notice on
behalf of the HHS Interagency Task
Force on Antimicrobial Resistance. The
draft Action Plan and supporting
documents can be found at https://
www.regulations.gov.
Written comments must be
received on or before April 15, 2011.
Comments received after April 15, 2011
will be considered to the fullest extent
possible.
DATES:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Draft Action Plan—A Public Health
Action Plan To Combat Antimicrobial
Resistance
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (DHHS).
ACTION: Notice of availability and
request for public comment.
jlentini on DSKJ8SOYB1PROD with NOTICES
AGENCY:
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS) is publishing
this notice requesting public comment
on the draft A Public Health Action Plan
to Combat Antimicrobial Resistance.
SUMMARY:
VerDate Mar<15>2010
16:56 Mar 15, 2011
Jkt 223001
Written comments may be
submitted to the following address:
Centers for Disease Control and
Prevention, National Center for
Emerging and Zoonotic Infectious
Diseases, Division of Healthcare Quality
Promotion, Office of Antimicrobial
Resistance, Attn: Antimicrobial
Resistance Action Plan, Docket No.
CDC–2011–0002, 1600 Clifton Rd., NE.,
Mailstop A–07, Atlanta, Georgia 30333.
You may also submit written
comments electronically to: https://
www.regulations.gov. All comments
received will be posted publicly without
change, including any personal or
proprietary information provided. To
download an electronic version of the
plan, access https://www.regulations.gov.
ADDRESSES:
[Docket No. CDC–2011–0002]
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Written comments, identified by
Docket No. CDC–2011–0002 will be
available for public inspection Monday
through Friday, except for legal
holidays, from 9 a.m. until 5 p.m.,
Eastern Daylight Time, at 1600 Clifton
Road, NE., Atlanta, Georgia 30333.
Please call ahead to (404) 639–4000 and
ask for a representative from the Office
of Antimicrobial Resistance to schedule
your visit. Comments may also be
viewed at https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Rachel Wolf, Centers for Disease Control
and Prevention, National Center for
Emerging and Zoonotic Infectious
Diseases, Division of Healthcare Quality
Promotion, Office of Antimicrobial
Resistance; 1600 Clifton Road, NE.,
Mailstop A–07, Atlanta, Georgia 30333,
(404) 639–4000.
SUPPLEMENTARY INFORMATION: The HHS
Interagency Task Force on
Antimicrobial Resistance (hereafter
referred to as the Task Force) was
created in 1999 to coordinate the
activities of Federal agencies in
addressing antimicrobial resistance (AR)
in recognition of the increasing
importance of AR as a public health
threat. The Task Force is co-chaired by
E:\FR\FM\16MRN1.SGM
16MRN1
]]>Agencies
[Federal Register Volume 76, Number 51 (Wednesday, March 16, 2011)]
[Notices]
[Pages 14401-14402]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-6106]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30-Day-11-0338]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-5960 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-5806.
Written comments should be received within 30 days of this notice.
[[Page 14402]]
Proposed Project
Annual Submission of the Ingredients Added to, and the Quantity of
Nicotine Contained in, Smokeless Tobacco Manufactured, Imported, or
Packaged in the U.S. (OMB No. 0920-0338, exp. 4/30/2011)--Extension--
Office on Smoking and Health, National Center for Chronic Disease
Prevention and Health Promotion (NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC), Office on
Smoking and Health (OSH) has the primary responsibility for the
Department of Health and Human Services (HHS) smoking and health
program. HHS's overall goal is to reduce death and disability resulting
from the use of smokeless tobacco products and other forms of tobacco
use through programs of information, education and research.
Since 1994, as required by the Comprehensive Smokeless Tobacco
Education Act of 1986 (CSTHEA, 15 U.S.C. 4401 et seq., Public Law 99-
252), CDC has collected information about the ingredients used in
smokeless tobacco products and their nicotine content. Respondents are
commercial smokeless tobacco product manufacturers, packagers, or
importers (or their representatives), who are required by the CSTHEA to
submit ingredient reports to HHS on an annual basis.
Respondents are not required to submit specific forms; however,
they are required to meet reporting guidelines and to submit the
ingredient report by chemical name and Chemical Abstract Service (CAS)
Registration Number, consistent with accepted reporting practices for
other companies currently required to report ingredients added to other
consumer products. Typically, respondents submit a summary report to
CDC with the ingredient information for multiple products, or a
statement that there are no changes to their previously submitted
ingredient report.
Ingredient reports for new products are due at the time of first
importation. Thereafter, ingredient reports are due annually on March
31. Information is submitted to OSH by mailing a written report on the
respondent's letterhead, by CD, three-inch floppy disk, or thumb drive.
Electronic mail submissions are not accepted.
Upon receipt and verification of the annual ingredient and nicotine
data reports, OSH issues a Certificate of Compliance to the respondent.
OSH also uses the information to report to the Congress (as deemed
appropriate) discussing the health effects of these ingredients.
In this Extension request, there are no changes to the estimated
number of respondents, the estimated burden per response, or the
information collection methods. There are no costs to respondents other
than their time. The total estimated annualized burden hours are
18,843.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Smokeless Tobacco Manufacturers, Packagers, and Importers.... 11 1 1,713
----------------------------------------------------------------------------------------------------------------
Dated: March 10, 2011.
Carol E. Walker,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2011-6106 Filed 3-15-11; 8:45 am]
BILLING CODE 4163-18-P
